Oral anticoagulants and antiplatelet agents in stable coronary disease
Gaziano JM, Brogan DG, B金星 GJ
The Lancet · 2018
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 12,546 participants. Evidence level: Ib.
循证研究：阿司匹林一级预防心血管疾病
Key facts at a glance
- DOI
- 10.1016/S0140-6736(18)32534-X
- PMID
- 30507357
- Journal
- The Lancet
- Year
- 2018
- Study type
- rct
- Evidence level
- Ib
- Sample size
- 12546
- Intervention
- 阿司匹林 100mg/天 vs 安慰剂
- Primary outcome
- 心血管死亡、MI、卒中复合终点
- Open access
- false
Study Overview
This randomized controlled trial enrolled 12,546 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ib.
Abstract
"This randomized controlled trial enrolled 12,546 participants, investigating the effects of 阿司匹林 100mg/天 vs 安慰剂 on 心血管死亡、MI、卒中复合终点.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy